Hamidah Abu Bakar1*, Nor Akmal Yati Sulong1, Nadiah Abdul Ghaffar2, Sharifah Izwan Tuan Othman2, Ahmad Norasidi bin Mohd Raffie2, Amjad Al-Khdhairawi3, Jean-Frederick Faizal Weber Abdullah3, Wan Amir Nizam Wan Ahmad4
1. Faculty of Pharmacy, University College MAIWP International, Jalan 31/10A, Taman Batu Muda, Batu Caves, 68100 Kuala Lumpur, Malaysia
2. Fakulti Sains Kesihatan UNISEL, Jalan Zirkon A7/A, Seksyen 7, 40000 Shah Alam, Selangor, Malaysia
3. Atta-ur-Rahman Institute for Natural Product Discovery (AuRIns), Level 9, FF3 Building, UiTM Puncak Alam Campus, 42300 Puncak Alam, Selangor, Malaysia
4. School of Health Sciences, USM Health Campus, 16150 Kubang Kerian, Kelantan, Malaysia
*Corresponding author: Hamidah Abu Bakar.
ABSTRACT
INTRODUCTION: Hypertension remains a major contributor to global morbidity and mortality, with current therapies often limited by adverse effects and suboptimal efficacy. Endophytic fungi have emerged as promising alternative sources of bioactive compounds for vascular modulation.
OBJECTIVES: This study aimed to evaluate the vasorelaxant effect of Aspergillus sp. HAB10R12 extract and investigates the interaction of Aspergillinine A, a diketopiperazine compound isolated from the same fungus, with key vascular targets through in vitro and in silico approaches.
MATERIALS AND METHODS: Thoracic aortic rings from Sprague-Dawley rats (220–250 g, n ≥ 6) were mounted in a multichannel myograph and equilibrated in Krebs–Henseleit solution. Rings were precontracted with phenylephrine before being exposed to cumulative concentrations of HAB10R12 extract (1 nM–300 µM). Methylene blue (10 µM), indomethacin (10 µM), and N-ω-nitro-L-arginine methyl ester (L-NAME, 100 µM) were used to assess involvement of nitric oxide (NO), prostacyclin, and endothelium-derived pathways. Molecular docking was conducted using AutoDock Vina and UCSF Chimera to study Aspergillinine A interactions with vascular targets—ETA, CaV1.2, and AT1R (PDB ID: 4AYA). Losartan was included as a standard reference. Pharmacokinetic and toxicity predictions were performed using SwissADME and ProTox-II.
RESULTS: HAB10R12 extract induced dose-dependent vasorelaxation with an IC₅₀ of 21.8 nM. The presence of methylene blue, indomethacin, or L-NAME did not attenuate the response, indicating a non-endothelium-dependent mechanism. Aspergillinine A exhibited stable binding to all three vascular targets via hydrogen bonding and hydrophobic interactions. Pharmacokinetic analysis using SwissADME predicted high gastrointestinal absorption and good oral bioavailability. The compound complied with Lipinski’s rule of five and other drug-likeness criteria. Toxicological predictions from ProTox-II classified Aspergillinine A as low-risk, with no strong evidence of hepatotoxicity, mutagenicity, or carcinogenicity.
CONCLUSION:
The findings support the vasorelaxant potential of Aspergillus sp. HAB10R12 and its diketopiperazine derivative, Aspergillinine A, highlight their promise as candidates for novel antihypertensive drug development.
KEYWORDS: Vasorelaxation, Aspergillinine A, In silico, Pharmacokinetics, HAB10R12


